Batting Eyelashes and All

May 27, 2008

Japan's biggest drug maker is making eyes at the US market as its patents get closer to their expiration dates. Takeda Pharmaceutical said it would pay $100 million to be Alnylam Pharmaceuticals' strategic partner in RNAi therapeutics, says the Wall Street Journal.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Pause Recommended

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

Science and a Side of Diplomacy

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

New Studies of B.1.1.7

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

PNAS Papers on Acute Kidney Injury, Parental Expression in Horse Placenta, Sea Urchin Microbes

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.

Menu